Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Clenbuterol toxicity: a NSW Poisons Information Centre experience

- Featured Image

Clenbuterol is a β2-adrenergic agonist with a long half-life of around 25–40 hours and high bioavailability,1 currently registered in Australia as a Schedule 4 medicine for veterinary use.2 It is marketed in tablet, gel and injectable forms as an equine bronchodilator and a bovine tocolytic agent. Its anabolic properties have seen it used in food-producing animals to increase lean meat yield.3 However, concerns about toxicity to humans from contaminated meat led to its use for this purpose being banned in the United States in 1991 and the European Union in 1996. Since then, there have been outbreaks of clenbuterol toxicity from contaminated meat across Europe and China,46 and outbreaks of clenbuterol contamination of heroin.7

The spectrum of toxicity in humans includes sympathomimetic effects such as restlessness, tachycardia and tachyarrhythmias,8 gastrointestinal disturbances and rhabdomyolysis, and metabolic disturbances such as hyperglycaemia and hypokalaemia. There have also been case reports of myocardial ischaemia…